Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis

Participants were given 210 mg romosozumab once monthly and compared with those given 20 mcg teriparatide daily for 12 months.⁸ STRUCTURE included postmenopausal osteoporotic women (n=436) averaging 72 years, with a history of non-vertebral fracture after age 50 or vertebral fracture and treatment with bisphosphonate therapy for a minimum of three years prior to transitioning to romosozumab or teriparatide therapy. For secondary endpoints, romosozumab-treated patients had significantly greater increases in BMD from baseline and increases in strength compared with teriparatide-treated patients.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Amgen Inc. FDA accepts Amgen’s supplemental biologics license application for the expanded use of enbrel (etanercept) to treat pediatric patients with chronic severe plaque psoriasis. 2016 Mar 10.
2. Bird Rock Bio Inc. Bird Rock Bio’s gerilimzumab, an anti-IL-6 antibody, demonstrates potential for affordable global access to a novel biologic to treat rheumatoid arthritis. 2016 Mar 16.
3. Axsome Therapeutics Inc. Axsome Therapeutics initiates phase 3 study of AXS-02 for knee osteoarthritis associated with bone marrow lesions. 2016 Mar 28.
4. U.S. Food and Drug Administration. FDA approves new psoriasis drug Taltz. 2016 Mar 22.
5. U.S. Food and Drug Administration. Taltz label information. 2016 Mar 22.
6. Swift D. Benlysta found steroid-sparing in lupus: Modest effects in prednisone dose reduction seen in post-hoc analyses. MedPage Today. 2016 Mar 26.
7. UCB. UCB and Amgen announce positive topline results from phase 3 study evaluating romosozumab in men with osteoporosis. 2016 Mar 21.
8. Amgen Inc. Amgen and UCB present positive data at ENDO 2016 comparing romosozumab with teriparatide. 2016 Apr 1.